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Control of food intake and energy expenditure by
amylin-therapeutic implications
Abstract
Amylin is a pancreatic B-cell hormone that plays an important role in the control of nutrient fluxes
because it reduces food intake, slows gastric emptying, and reduces postprandial glucagon secretion.
These actions seem to depend on a direct effect on the area postrema (AP). Subsequent to area AP
activation, the amylin signal is conveyed to the forebrain via distinct relay stations. Within the lateral
hypothalamic area, amylin diminishes the expression of orexigenic neuropeptides. Recent studies
suggest that amylin may also play a role as a long term, adiposity signal. Similar to leptin or insulin, an
infusion of amylin into the brain resulted in lower body weight gain than in controls, irrespective of the
starting body weight. Interestingly, preliminary data also suggest that rats fed an energy-dense diet
develop resistance to central amylin. In addition to amylin's action to control meal termination and to act
as a potential adiposity signal, amylin and its agonist salmon calcitonin have recently been shown to
increase energy expenditure under certain conditions. In summary, amylin may be an interesting target
as a body weight lowering drug. In fact, recent studies provide evidence that amylin, especially when
combined with other anorectic hormones (for example, peptide YY and leptin) has beneficial long-term
effects on body weight.
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Abstract 
Amylin is a pancreatic B-cell hormone that plays an important role in the control of nutrient 
fluxes because it reduces food intake, slows gastric emptying and reduces postprandial 
glucagon secretion. These actions seem to depend on a direct effect on the area postrema (AP). 
Subsequent to AP activation, the amylin signal is conveyed to the forebrain via distinct relay 
stations. Within the lateral hypothalamic area, amylin diminishes the expression of orexigenic 
neuropeptides. Recent studies suggest that amylin may also play a role as a long term, 
adiposity signal. Similar to leptin or insulin, an infusion of amylin into the brain resulted in 
lower body weight gain than in controls, irrespective of the starting body weight. Interestingly, 
preliminary data also suggest a resistance to central amylin in rats fed a calorie-dense diet. In 
addition to amylin’s action to control meal termination and to act as a potential adiposity 
signal, amylin and its agonist salmon calcitonin (sCT) have recently been shown to increase 
energy expenditure under certain conditions. In summary, amylin may be an interesting target 
as a body weight lowering drug. In fact, recent studies provide evidence that amylin, 
especially when combined with other anorectic hormones (e.g., PYY and leptin) has 
beneficial long-term effects on body weight. 
Keywords: amylin, satiation, adiposity signal, energy expenditure, cocktail therapy 
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Introduction 
Amylin is a pancreatic B-cell hormone coreleased with insulin in response to food intake. 
Amylin reduces eating, gastric acid secretion, limits the rate of gastric emptying, and 
diminishes pancreatic glucagon secretion (1). These actions, in particular amylin’s effect on 
gastric emptying and glucagon secretion, are the basis for the use of amylin analogues in the 
treatment of type 2 diabetes mellitus (2-3). Regarding the control of eating, amylin is among 
the more interesting hormones affecting food intake. In addition to amylin’s effect to control 
meal size, several studies suggest that amylin may also be involved in the long term control of 
food intake and body weight, sharing characteristics with adiposity signals (4-5). 
Amylin is a satiating signal 
The best-studied function of amylin is its role as a hormone contributing to meal termination 
(1, 6). Amylin shares the characteristics typical of satiating hormones such as cholecystokinin 
(CCK) (7). First, amylin is released during food ingestion, and it dose-dependently reduces 
meal size. Second, after a single peripheral injection, amylin has a rapid onset and brief 
duration of action. Third, the anorectic action of amylin appears to be specific, as amylin does 
e.g. not reduce feeding by producing a conditioned taste aversion or by an unspecific effect 
(e.g. via a reduction in drinking). The lowest dose of exogenous amylin that produced a 
significant reduction in feeding yielded plasma amylin levels that were only slightly higher 
than the concentrations measured postprandially. Finally, amylin seems to be a physiological 
control of meal size because amylin antagonists produce the opposite effect, i.e., they increase 
eating, mainly via a meal size effect (8-9). 
Primary site for amylin-mediated satiation  
Experimental evidence supports the idea that the satiating effect of peripheral amylin is 
mediated by direct humoral action on the area postrema (AP) in the hindbrain (e.g., 9-11), an 
area that lacks a functional blood brain barrier. Behavioural studies showed that whereas 
amylin’s effect is abolished in rats with lesions in the AP/NTS region (10-11), none of the 
techniques that block nerval afferent information from the periphery to the brain was able to 
abolish the anorectic action of peripheral amylin (e.g., 12). An infusion of the amylin 
antagonist AC 187 into the AP increased food intake due to an increase in meal size. AC 187 
infused into the AP also reduced the anorectic effect of peripheral amylin (9). Feeding studies 
were complemented by electrophysiological and immunohistochemical studies (6, 13-14). A 
direct, dose-dependent stimulating effect of amylin on AP neurons underlines their sensitivity 
to amylin. Further, peripheral amylin produced a strong expression of the immediate early 
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gene product c-Fos protein as a marker of neuronal activation in AP neurons. The latter may 
be linked to the generation of cGMP in amylin target cells (6).  
Recently, we unexpectedly observed that low doses of amylin induced very little c-Fos in the 
AP in ad libitum chow fed rats, but amylin caused a strong c-Fos expression in food deprived 
rats and in rats that received a nutrient-deficient non-caloric mash (NCM). After 
supplementation of NCM with single nutrients, rats fed NCM supplemented with glucose or 
fat displayed an equally strong amylin-induced activation as fasted rats or rats fed plain NCM. 
c-Fos expression was significantly lower when rats were fed a protein supplemented NCM. 
Further, amylin failed to reduce food intake in NCM/protein fed rats, whereas amylin caused 
a reduction in feeding when animals received NCM, NCM/glucose or NCM/fat. Interestingly, 
amylin effectively reduced food intake in ad libitum chow fed rats despite the lack of a 
prominent amylin-induced c-Fos expression in the AP under these conditions, perhaps 
pointing to a partially Fos-independent action of amylin. Overall, amylin’s anorectic potential 
may be attenuated by large amounts of protein in the diet, whereas this effect appears to be 
overridden when the amount of carbohydrates/fat is high relative to the protein content such 
as e.g. in standard chow (15). 
Pathways beyond the AP 
Peripheral administration of amylin elicits a strong c-Fos response in projection areas of the 
AP, i.e. in the NTS, the lateral parabrachial nucleus (lPBN), the central nucleus of the 
amygdala (CeNA), and the bed nucleus of the stria terminalis (BNST) (13-14). Their 
activation seems to be secondary to an action of amylin on AP neurons. Activation of the 
lPBN, but not the CeNA, seems to be a necessary part in the signalling cascade for amylin’s 
anorectic effect (16). 
The exact pathways used by amylin beyond the lPBN are currently under investigation. 
Previously, we provided evidence that the lateral hypothalamic area (LHA) may play a role in 
amylin’s anorectic effect (14, 17). Recent studies with anterograde and retrograde neuronal 
tracers support the idea that amylin-activated neurons in the lPBN project to the subregion of 
the LHA that is affected by amylin administration (Lutz et al., unpublished). 
Interaction of amylin with other hormones 
Amylin and CCK 
Food intake leads to the release of a multitude of gastrointestinal peptide hormones. This 
“cocktail” of hormones (e.g., amylin, CCK, peptide YY, etc.) may be a more precise signal to 
the brain regarding the amount and composition of ingested food than that of a single signal. 
Relatively little is known about the specific release of the various gastrointestinal feedback 
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signals and their interaction. We recently studied the interaction of amylin and CCK and 
found that amylin seems to be a necessary modulator of CCK’s anorectic action because 
amylin knockout mice, e.g., have a blunted feeding response to exogenous CCK which can be 
rescued by the injection of low, subthreshold doses of amylin (18-19).  
Amylin and leptin or insulin 
Adiposity signals modulate the effect of satiating hormones, i.e. both leptin and insulin affect 
the potency of CCK to reduce meal size (reviewed e.g. in 5). Eiden et al (20) showed that 
rodent models with a defective leptin signalling system have a reduced response to anorectic 
doses of the amylin agonist salmon calcitonin (sCT). Recently, we showed that food intake 
was reduced more in rats receiving a third ventricular (I3vt) administration of leptin and an 
intraperitoneal injection of amylin than by either peptide alone. Further, a subthreshold dose 
of I3vt insulin significantly enhanced the response to peripheral amylin, and combined 
peripheral administration of subthreshold doses of insulin and amylin significantly reduced 
food intake in rats (21-22). This may indicate that the adiposity signals leptin and insulin 
interact with amylin to reduce food intake (21). In contrast, we (21) and others (23) found no 
evidence for an interaction between the orexigenic hormone ghrelin and amylin. 
Pharmacological tests with cocktail treatments including amylin 
The first clinical tests involving amylin that were part of a program for the development of 
antidiabetic drugs showed that in patients who received insulin plus amylin replacement (in 
the form of the amylin analog pramlintide), food intake and body weight were decreased more 
than in patients receiving insulin alone (3). Follow up studies indicated that amylin may be an 
interesting option in the treatment of obesity. Most pronounced effects were observed when 
amylin was combined with leptin, or in a triple combination with PYY and leptin (R&D 
Information, Amylin Inc.). 
Summary of the central nervous system mechanisms mediating amylin’s effect on food 
intake 
We propose the following central nervous system pathway. Amylin released from pancreatic 
B-cells in response to food intake seems to have a direct hormonal action on AP neurons that 
project via the NTS and lPBN to higher brain centers. Preliminary data indicate that amylin-
activated lPBN neurons project to a specific LHA subregion. Some studies also indicate that 
the ventromedial hypothalamus (VMH) may be involved in this pathway via histaminergic 
transmission (24). Site and mechanism of interaction between amylin and other anorectic 
hormones (e.g., CCK, PYY, leptin, insulin) remain to be established. 
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Amylin as an adiposity signal 
Amylin differs from pure satiating signals because it may also play a role as an adiposity 
signal (4, 10, 25-26). Similar to leptin and insulin, the basal levels of amylin depend on the 
prevailing body adiposity. In rats, chronic amylin infusion lowers food intake and body 
weight gain by reducing body adiposity. Chronic peripheral or central infusion of amylin 
antagonists increases body weight with a major effect on an increase in body fat (4). 
Therefore, the effect of a chronic modulation of the central amylin signalling system seems to 
be similar to that of leptin or insulin.  
Chavez et al (27) showed that during chronic central insulin infusion, previously food-
deprived rats and ad libitum fed rats attained a similar level of body weight that was markedly 
below the level of respective saline infused control rats. Based on this study, we injected rats 
once daily with the amylin agonist salmon calcitonin (sCT) or saline for nine consecutive 
days. Half of the saline and half of the sCT treated rats did not receive food for the first two 
days into the study. Similar to the study by Chavez and colleagues (27), both groups of 
animals caught up in body weight with their counterparts that had not been food deprived but 
received the same treatment (sCT or saline). Similarly, in rats chronically infused with amylin 
or saline into the third cerebral ventricle, all amylin-treated animals achieved a similar body 
weight at the end of infusion that was significantly below that of saline controls. These studies 
suggest that both central insulin and amylin determine the level of body weight maintained by 
the animal. In a third experiment, we overfed some of the rats before amylin infusion by 
offering them a calorie-dense diet (Ensure®) in addition to standard chow. To our surprise, 
animals overfed for three weeks appeared to be resistant to the body weight lowering effect of 
amylin. The underlying mechanisms are currently under investigation. 
At present, it is difficult to judge how the quantitative contribution of amylin to the control of 
body weight compares with that of leptin or insulin. The amylin-deficient mouse (6) clearly 
shows less of an obese phenotype than e.g. the leptin-deficient ob/ob mouse. This may imply 
that under conditions when baseline amylin levels are normal and when other adiposity signal 
systems are functional, the relevance of amylin as adiposity signal is minor. However, when 
the leptin and insulin feedback signalling systems are deficient, amylin may play some role as 
an adiposity signal and at least partly take over the function of leptin and insulin (28). 
Amylin increases energy expenditure 
The adiposity signal leptin is known to increase energy expenditure under appropriate 
conditions. Based on previous reports that amylin may increase body temperature, we recently 
investigated whether amylin or sCT shares leptin’s effects on energy expenditure. While the 
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acute administration of amylin failed to affect energy expenditure in rats, the amylin agonist 
sCT significantly stimulated energy expenditure in fasted animals (29). Chronic amylin 
administration was shown to either increase energy expenditure, at least when expressed 
relative to body weight (30), or to prevent the decrease in energy expenditure that was seen in 
animals whose food intake was yoked with that of amylin-treated rats (unpublished). In any 
case, amylin seems to prevent the compensatory decrease in energy expenditure normally 
seen in animals that eat less.  
Summary 
Amylin seems to be a physiological regulator of meal size. Most studies indicate that the 
effect of peripheral amylin is centrally mediated via the AP. Chronic exposure to amylin 
decreases food intake and body weight gain. Next to its induction of satiation, amylin may 
also constitute one of the body’s adiposity signals. Amylin analogs are under clinical 
consideration for their effect to reduce food intake and body weight in humans, especially in 
type 2 diabetics. 
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